413 related articles for article (PubMed ID: 35596213)
1. Real-world study of multiple naloxone administration for opioid overdose reversal among bystanders.
Abdelal R; Raja Banerjee A; Carlberg-Racich S; Darwaza N; Ito D; Shoaff J; Epstein J
Harm Reduct J; 2022 May; 19(1):49. PubMed ID: 35596213
[TBL] [Abstract][Full Text] [Related]
2. The need for multiple naloxone administrations for opioid overdose reversals: A review of the literature.
Abdelal R; Banerjee AR; Carlberg-Racich S; Darwaza N; Ito D; Epstein J
Subst Abus; 2022; 43(1):774-784. PubMed ID: 35112993
[No Abstract] [Full Text] [Related]
3. Real-world study of multiple naloxone administrations for opioid overdose reversal among emergency medical service providers.
Abdelal R; Banerjee AR; Carlberg-Racich S; Cebollero C; Darwaza N; Kim C; Ito D; Epstein J
Subst Abus; 2022; 43(1):1075-1084. PubMed ID: 35442869
[No Abstract] [Full Text] [Related]
4. Use of naloxone nasal spray 4 mg in the community setting: a survey of use by community organizations.
Avetian GK; Fiuty P; Mazzella S; Koppa D; Heye V; Hebbar P
Curr Med Res Opin; 2018 Apr; 34(4):573-576. PubMed ID: 28535115
[TBL] [Abstract][Full Text] [Related]
5. Patient perceptions of higher-dose naloxone nasal spray for opioid overdose.
Strickland JC; Marks KR; Smith KE; Ellis JD; Hobelmann JG; Huhn AS
Int J Drug Policy; 2022 Aug; 106():103751. PubMed ID: 35636070
[TBL] [Abstract][Full Text] [Related]
6. A Novel Faster-Acting, Dry Powder-Based, Naloxone Intranasal Formulation for Opioid Overdose.
Lapidot T; Bouhajib M; Faulknor J; Khan S; Krayz GT; Abrutzky C; Megiddo D
Pharm Res; 2022 May; 39(5):963-975. PubMed ID: 35386013
[TBL] [Abstract][Full Text] [Related]
7. Bystander preference for naloxone products: a field experiment.
Marks KR; Oyler DR; Strickland JC; Jaggers J; Roberts MF; Miracle DK; Barnes C; Lei F; Smith A; Mackin E; Martin MC; Freeman PR
Harm Reduct J; 2023 Nov; 20(1):171. PubMed ID: 38017424
[TBL] [Abstract][Full Text] [Related]
8. Naloxone (Narcan) nasal spray for opioid overdose.
Med Lett Drugs Ther; 2016 Jan; 58(1485):1-2. PubMed ID: 26714239
[No Abstract] [Full Text] [Related]
9. Nalmefene nasal spray (Opvee) for reversal of opioid overdose.
Med Lett Drugs Ther; 2023 Oct; 65(1687):166-167. PubMed ID: 37871116
[No Abstract] [Full Text] [Related]
10. Pharmacokinetic considerations for community-based dosing of nasal naloxone in opioid overdose in adults.
Dale O
Expert Opin Drug Metab Toxicol; 2022 Mar; 18(3):203-217. PubMed ID: 35500297
[TBL] [Abstract][Full Text] [Related]
11. Amount of naloxone used to reverse opioid overdoses outside of medical practice in a city with increasing illicitly manufactured fentanyl in illicit drug supply.
Bell A; Bennett AS; Jones TS; Doe-Simkins M; Williams LD
Subst Abus; 2019; 40(1):52-55. PubMed ID: 29558283
[No Abstract] [Full Text] [Related]
12. In brief: Higher-dose naloxone nasal spray (Kloxxado) for opioid overdose.
Med Lett Drugs Ther; 2021 Sep; 63(1633):151-152. PubMed ID: 34550963
[No Abstract] [Full Text] [Related]
13. Naloxone administration by law enforcement officers in New York State (2015-2020).
Pourtaher E; Payne ER; Fera N; Rowe K; Leung SJ; Stancliff S; Hammer M; Vinehout J; Dailey MW
Harm Reduct J; 2022 Sep; 19(1):102. PubMed ID: 36123614
[TBL] [Abstract][Full Text] [Related]
14. Comparative Human Factors Evaluation of Two Nasal Naloxone Administration Devices: NARCAN
Tippey KG; Yovanoff M; McGrath LS; Sneeringer P
Pain Ther; 2019 Jun; 8(1):89-98. PubMed ID: 30877583
[TBL] [Abstract][Full Text] [Related]
15. High-dose naloxone formulations are not as essential as we thought.
Lemen PM; Garrett DP; Thompson E; Aho M; Vasquez C; Park JN
Harm Reduct J; 2024 May; 21(1):93. PubMed ID: 38741224
[TBL] [Abstract][Full Text] [Related]
16. Estimating naloxone need in the USA across fentanyl, heroin, and prescription opioid epidemics: a modelling study.
Irvine MA; Oller D; Boggis J; Bishop B; Coombs D; Wheeler E; Doe-Simkins M; Walley AY; Marshall BDL; Bratberg J; Green TC
Lancet Public Health; 2022 Mar; 7(3):e210-e218. PubMed ID: 35151372
[TBL] [Abstract][Full Text] [Related]
17. Naloxone Dosing After Opioid Overdose in the Era of Illicitly Manufactured Fentanyl.
Carpenter J; Murray BP; Atti S; Moran TP; Yancey A; Morgan B
J Med Toxicol; 2020 Jan; 16(1):41-48. PubMed ID: 31471760
[TBL] [Abstract][Full Text] [Related]
18. Personal experience and awareness of opioid overdose occurrence among peers and willingness to administer naloxone in South Africa: findings from a three-city pilot survey of homeless people who use drugs.
Wilson M; Brumwell A; Stowe MJ; Shelly S; Scheibe A
Harm Reduct J; 2022 Feb; 19(1):17. PubMed ID: 35148779
[TBL] [Abstract][Full Text] [Related]
19. Take-Home Naloxone Kits: Attitudes and Likelihood-Of-Use Outcomes from a European Survey of Potential Overdose Witnesses.
McDonald R; Breidahl S; Abel-Ollo K; Akhtar S; Clausen T; Day E; Kelleher M; McAuley A; Petersen H; Sefranek M; Thiesen H; Strang J
Eur Addict Res; 2022; 28(3):220-225. PubMed ID: 35114666
[TBL] [Abstract][Full Text] [Related]
20. An exploratory study of a hands-on naloxone training for rural clinicians and staff.
Cody SL; Hines CB; Glenn CJ; Sharp-Marbury R; Newman S
J Nurs Scholarsh; 2023 May; 55(3):599-604. PubMed ID: 36411494
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
